Dr. Rafat Taher was the former Executive Director of Development and Implementation at InterHealth Canada. He was a general sergeant
Abdulmohsen Almajnouni is currently the Chief Executive Officer (CEO) of Research Products Development Company (RPDC). Prior to that, he was the Executive Director of the Strategic Initiatives and as well the Managing Director of Energy and downstream chemicals industry, Saudi Arabia General Investment Authority (SAGIA).
He has more than 24 years of experience in gas processing and treating, refining and petrochemicals, utilities, and exploration and production. Abdulmohsen was previously the Refining and Petrochemical Leader for General Electric in Saudi Arabia, promoting GE’s products and services in the region. He had prior experience as the Global Process Domain Director at SABIC’s Manufacturing Center of Excellence, and consulted on process engineering for SABIC’s sites. He began his career at Saudi Aramco in 1988, before moving to other industrial experiences.
Abdulmohsen earned a BS from King Fahd University of Petroleum and Minerals, and a Master of Engineering from Cornell Univers
ity, Ithaca, NY, USA, both in chemical engineering. He is the chair of American Institute of Chemical Engineers (AIChE) Saudi Arabia Section (SAS-AIChE) and a member of AIChE’s International Committee.
Consultant Radiation Oncologist
Head of Radiation Oncology, Princess Norah Oncology Center
Head of King Abdullah International Medical Research Center Jeddah (KAIMRC-J)
Deputy Chairman of Princess Norah Oncology Center, KAMC-WR, NGHA
Dr. Suliman Al Ghamdi joined King Abdulaziz Medical City, Western Region in August 2005 as Associate Consultant, Department of Oncology, and promoted to Consultant position in 2007 and was appointed as Section Head, Radiation Oncology in August 2007. In August 2010, he was appointed as Deputy Chairman, Princess Nourah Oncology Center, King Abdulaziz Medical City, Western Region. In August 2011, he was appointed as Deputy Head, King Abdullah International Medical Research Center, Western Region. In August 13, 2013, Dr. Ghamdi was appointed as the Head of King Abdullah International Medical Research Center – Western Region and up to now is still the head of the Research Center in Jeddah.
Dr. Suliman Al Ghamdi graduated from King Abdulaziz University, Faculty of Medicine, Jeddah, Saudi Arabia in 1997, and completed his internship in the same institution in 1998. He completed his Residency Training Program in Radiation Oncology from January 2000 till December 2004 at Ottawa Regional Cancer Centre, University of Ottawa, Ontario, Canada, followed by fellowship training in Radiation Oncology with sub – specialization in Stereotactic Radiosurgery of Head and Neck, CNS Malignancies and Brachytherapy in 2005. He also obtained FRCPC certificate on May 28, 2004.
Dr. Dunia Jawdat is the Director of the Cord Blood Bank and Saudi Stem cell donor registry at King Abdullah International Medical Research Center. She is a Research Scientist in the field of Immunology and Stem Cells. She holds a PhD in immunology, from the Department of Pathology at Dalhousie University in Canada. Dr. Dunia Jawdat holds the american board of medical laboratory immunology. She is an Associate professor of immunology in the college of medicine at King Saud bin Abdulaziz University for Health Sciences. She is an active FACT inspector in the field of cellular therapy and cord blood banking. She is a member of the International Society For Cellular Therapy (ISCT), the Canadian Society of Immunologists (CSI), the American Society of Histocompatibility and Immunogenetics (ASHI) and the Saudi Scientific Society of Blood and Marrow Transplantation (SSBMT).
Chief of Drug Evaluators Drug Sector , SFDA
He led the process of establishing the pharmaceutical products evaluation directorate at SFDA, which is the scientific backbone of the drug sector since 2009. Dr. Almazroo was the first director appointed for pharmaceutical products evaluation. With his colleagues, he developed many of the current scientific practices in the directorate. He also initiated, coordinated and conducted two clinical studies at the University of Pittsburgh Medical Center (UPMC), one of which was Phase I/II – Investigational New Drug (IND) clinical study.
Dr. Almazroo graduated from School of Pharmacy, King Saud University with a Bachelor degree in Pharmaceutical Sciences. In 2009, he was among the top 10% of all graduates in the Master of Sciences in biopharmaceuticals from School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia. On 27 April 2013, he was one of the first Saudi pharmacists to complete the Certificate in Clinical and Translational Sciences (master degree level) from the School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. In 2017, he received his PhD in Pharmaceutical Sciences from University of Pittsburgh. The PhD research was focused on hepatic ischemia and reperfusion injury in liver transplantation. He conducted preclinical and clinical studies, while his research involved in using ex-vivo, in-vivo and simulation models for pharmacokinetics, developed several mass spectrometry assays and utilized PCR techniques for gene characterization.
Advisor to the Minister for Pharmaceutical Sector Development
Ibrahim Aljuffali is the Executive Vice President for Drug Sector at Saudi FDA. Dr. Aljuffali earned his PhD degree in Pharmaceutical sciences from the University of Georgia (UGA) with research emphasis in Nontechnology and Pharmacokinetics/Pharmacodynamics. Dr. Aljuffali also earned a Master of Science Degree in Pharmacy with an emphasis in Regulatory Affairs and graduate diploma in Clinical Trials Design & Management from University of Georgia.
Dr. Aljuffali Also serve as an Associate Professor at King Saud University. He chairs and patriate in different local and national committee related to health and drug regulation.